No abstract

Corporate partners of the EDF have been asked to contribute towards this work. GlaxoSmithKline plc. (GSK) and Meda AB have contributed funding for the development of the European evidence-based (S3) guideline for the treatment of acne (update 2016) through an educational grant to the EDF. Sponsors had no influence on the content of the guideline. Support was given independent of any influence on methods or results. Sponsors did not receive any information about methods, group members or likely results. The sources of the funding were not known to the experts of the guideline and were not disclosed before the finalization of the guideline. This is a short summary of the complete version of the S3 European Acne guideline, please see online appendix for full text (Document S1. Long Version) and detailed methods report (DOI: 10.1111/jdv.13783). Expiry date: 31 December 2020 MethodsIn order to weight the different recommendations, the group assigned a 'strength of recommendation'. It considered all aspects of the treatment decision, such as efficacy, safety, patient preference and the reliability of the existing body of evidence. Strength of recommendationIn order to grade the recommendation a "standardized guideline" language was used:

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a rather distinct severe adverse drug reaction characterised by skin rash, fever, lymph node enlargement and internal organ involvement. Our aim was to review the available data regarding the management of this probably underrecognised subset of drug reaction. So far, the only undisputed way to treat severe hypersensitivity reactions is prompt withdrawal of the offending drug. The use of systemic corticosteroids remains controversial. The benefit of therapies aimed at accelerating the elimination of the causative drug deserves further studies. In the absence of a well-established therapy, primary and secondary prevention have a key role in the management of DRESS syndrome.

These results suggest a role of NGF in endometriotic pain and hyperalgesia in deep adenomyotic nodules. The strong expression of the NGF-TrkA pathway in deep adenomyotic nodules could explain why this type of lesion infiltrates in richly innervated anatomical sites.

No abstract